News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Healthcare day 2026

Apr 16, 2026 | ,

On April 14, IDL participated at Redeye Healthcare Day. CEO Anders Hultman presented the company and shared more about its strategy, current and future markets, and our joint venture with concile. Watch the presentation here

read more

CACLP and meeting with new distributor

Mar 27, 2026 | ,

During CACLP in Xiamen, China’s largest IVD exhibition, IDL Diagnostics had the opportunity to meet a wide range of industry players, exchange valuable insights, and further explore the fast-evolving Chinese IVD market. The trip concluded in Tianjin with our first...

read more

Partnership Meetings and CLIA Focus in China

Mar 20, 2026 | ,

Anders Hultman, Gustav Sten, Xia Jiang and Marie Torstensson have been in Shanghai, China, to meet our partners within CLIA. Currently, we have one product on the market, TPS CLIA, as well as two products in development: TK1 CLIA and UBC CLIA. The purpose of the...

read more